» Articles » PMID: 23341618

Aberrant Splicing of HTT Generates the Pathogenic Exon 1 Protein in Huntington Disease

Abstract

Huntington disease (HD) is a devastating, late-onset, inherited neurodegenerative disorder that manifests with personality changes, movement disorders, and cognitive decline. It is caused by a CAG repeat expansion in exon 1 of the HTT gene that translates to a polyglutamine tract in the huntingtin protein (HTT). The formation of HTT fragments has been implicated as an essential step in the molecular pathogenesis of HD and several proteases that cleave HTT have been identified. However, the importance of smaller N-terminal fragments has been highlighted by their presence in HD postmortem brains and by the fact that nuclear inclusions are only detected by antibodies to the N terminus of HTT. Despite an intense research effort, the precise length of these fragments and the mechanism by which they are generated remains unknown. Here we show that CAG repeat length-dependent aberrant splicing of exon 1 HTT results in a short polyadenylated mRNA that is translated into an exon 1 HTT protein. Given that mutant exon 1 HTT proteins have consistently been shown to be highly pathogenic in HD mouse models, the aberrant splicing of HTT mRNA provides a mechanistic basis for the molecular pathogenesis of HD. RNA-targeted therapeutic strategies designed to lower the levels of HTT are under development. Many of these approaches would not prevent the production of exon 1 HTT and should be reviewed in light of our findings.

Citing Articles

Glutamine missense suppressor transfer RNAs inhibit polyglutamine aggregation.

Tennakoon R, Bily T, Hasan F, Syal S, Voigt A, Balci T Mol Ther Nucleic Acids. 2025; 36(1):102442.

PMID: 39897579 PMC: 11787650. DOI: 10.1016/j.omtn.2024.102442.


The N17 domain of huntingtin as a multifaceted player in Huntington's disease.

Cho H Front Mol Biosci. 2025; 11():1527313.

PMID: 39845903 PMC: 11753208. DOI: 10.3389/fmolb.2024.1527313.


Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease.

Handsaker R, Kashin S, Reed N, Tan S, Lee W, McDonald T Cell. 2025; 188(3):623-639.e19.

PMID: 39824182 PMC: 11822645. DOI: 10.1016/j.cell.2024.11.038.


Detection of HTTex1p by western blot and immunostaining of HD human and mouse brain using neo-epitope antibody P90 highlights impact of CAG repeat expansion on its size, solubility, and response to MSH3 silencing.

Sapp E, Boudi A, Iwanowicz A, Belgrad J, Miller R, OReilly D bioRxiv. 2025; .

PMID: 39803497 PMC: 11722249. DOI: 10.1101/2024.12.31.630891.


A collaborative network analysis for the interpretation of transcriptomics data in Huntington's disease.

Ozisik O, Kara N, Abbassi-Daloii T, Terezol M, Kuijper E, Queralt-Rosinach N Sci Rep. 2025; 15(1):1412.

PMID: 39789061 PMC: 11718016. DOI: 10.1038/s41598-025-85580-4.


References
1.
Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S . Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 2010; 285(12):8808-23. PMC: 2838303. DOI: 10.1074/jbc.M109.075028. View

2.
Swanson C, Sherer N, Malim M . SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA. J Virol. 2010; 84(13):6748-59. PMC: 2903291. DOI: 10.1128/JVI.02526-09. View

3.
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C . Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996; 87(3):493-506. DOI: 10.1016/s0092-8674(00)81369-0. View

4.
Slow E, Van Raamsdonk J, Rogers D, Coleman S, Graham R, Deng Y . Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12(13):1555-67. DOI: 10.1093/hmg/ddg169. View

5.
Ross C, Tabrizi S . Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2010; 10(1):83-98. DOI: 10.1016/S1474-4422(10)70245-3. View